In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

Fresh from an alliance with Novartis, Chai Discovery has raised $400 million in third-round funding for its AI-based molecular design platform.

This link will take you to a page that’s not on LinkedIn

Novo Nordisk has joined forces with Amazon Web Services (AWS) on a project that will lead to the creation of an AI co-innovation hub in London.

Keystone Symposia charts the evolution of AI in biomedicine, from theory to application, shaping the future of life science research.

💭 Excited to discuss AI’s role in precision medicine? I’m looking forward to leading an insightful roundtable discussion on how AI is reshaping target…

Artificial intelligence (AI) continues to transform the healthcare landscape, offering innovative solutions to some of the most pressing medical challenges. One of the most promising developments is the use of AI to identify drug repurposing opportunities for diseases without effective treatments. Harvard Medical School's innovative model, TxGNN, represents a groundbreaking step in this direction. Introducing TxGNN: A New Approach to Drug Repurposing Developed by Dr. Marinka Zitnik and her team, TxGNN is a graph foundation model designed to predict therapeutic candidates for diseases with sparse or no treatment options. Unlike traditional drug-repurposing models that focus on a single disease, TxGNN is trained across a wide array of conditions.

In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

Artificial intelligence (AI) is rapidly transforming healthcare, from diagnosing diseases to discovering life-saving medications. Yet, understanding the role of AI in such a complex and evolving field can be challenging. Misinformation, technical jargon, and gaps in accessibility often leave us with more questions than answers. That’s why we’re here—to address your questions with factual, up-to-date, well-researched, and actionable information. In this series, we tackle the critical and nuanced topics shaping healthcare, ensuring you have the clarity and insights to navigate this AI-driven era confidently. Question from our readers: Are AI-Developed Drugs From Wealthy Nations Accessible in Lower-Income Countries?

The future of medicine is here, and artificial intelligence (AI) is leading the charge. In a significant development, Insilico Medicine, a biotechnology company at the forefront of AI-powered drug discovery, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for ISM5939. This AI-designed drug is set to enter clinical trials for the treatment of solid tumors, marking a pivotal moment in the fight against cancer. What Makes ISM5939 Unique? ISM5939 is no ordinary drug. It targets an enzyme called ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which plays a critical role in the progression of certain cancers.